Recruiting
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for Pulmonary Diseases
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Pulmonary Diseases
ClinicalTrials.gov IDNCT05147688
PhasePHASE1
Enrollment20
SponsorThe Foundation for Orthopaedics and Regenerative Medicine
AgeNot reported
SexALL
Conditions studied
Pulmonary Disease, Asthma, Chronic Obstructive Pulmonary Disease
About this study
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Pulmonary Diseases
Interventions
- Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells — cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Primary outcomes
- Safety (adverse events) (Four year follow-up)
Eligibility information
Inclusion Criteria:
* Diagnosis of pulmonary disease
* Understanding and willingness to sign a written informed consent document
Exclusion Criteria:
* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur
Study locations
- Prodromos Stem Cell Institute, Naples, Florida 34102 United States
- Prodromos Stem Cell Institute, Athens, Greece
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.